Bio-Pharmaceutical money considerable, the venture to compete for a new round of "Chong Rich Express"

Future biopharmaceutical development direction will probably expand to agriculture, energy and so on many aspects, no wonder VCs will have a special situation. Information picture "Previously, Chinese biomedical majors were unable to find work, but now biomedical focus on investors, there is a new round of opportunities to create wealth after the Internet." 26th, Kai Peng, the founding partner of Zhongxiaolin Investment Fund, said to our correspondent. Just a week ago, the company signed 15 million dollar venture capital project to one of the largest biomedical outsourcing companies in China, Kingstedt Technology (Nanjing) Co., Ltd.　　This is also the first investment in China's pharmaceutical industry this year. After the introduction of a number of policies to accelerate the development of the bio-industry, "more venture capital institutions will be inclined to invest in biotech companies."　　"Investors are flocking into the biopharmaceutical industry. According to a study published by Ezcapital, a domestic venture capital Research Institute, 88 cases of financing were reported in China's health care industry in 2006-2008, with an annual growth rate of 7.214 billion RMB and 45% per annum.　　In these financing events, the number of financing cases in the pharmaceutical manufacturing sector accounted for half of the total, and its financing amount is up to 4.862 billion yuan, accounting for 67.4% of total financing.　　Bio-Pharmaceutical Money: Multi-field development The China fund in China, launched in 2007, is in charge of 500 million of billions of dollars, and biomedicine is a new opportunity to create wealth after Zhongxiaolin's eyes relay the Internet. This time the Kingstedt technology (Nanjing) Co., Ltd. (hereinafter referred to as "Kingstedt") was established only 5 years, is a research and development, production and sales of bio-pharmaceutical companies, is China's rapid development in recent years, the main medicine C R O (c ontract R Esearcho Rganization Contract research Outsourcing).　　Kingstedt has now established 6 major experimental platforms: gene synthesis (including primer synthesis), PCR cloning, SiR N a construction, peptide synthesis, protein expression purification and antibody preparation, service range includes one-stop service from gene to antibody, and provides biotechnology services for early research and development of bioengineering and new drug screening. "Research and development outsourcing is not the most expensive labor-intensive industry in China in the past." The company must have high-quality biologists equipped to meet the requirements of customers to develop, design and produce the required bio-pharmaceutical products. "Zhongxiaolin said. High growth, high return is the Basic Law of investment in VC, Zhongxiaolin that the first stage of Kingstedt for Europe and the United States to do research and development outsourcing, can gain profits in the short term, accumulate capital, and more importantly, through outsourcing to participate in the Global Innovation Medicine research and development services, is actually involved in the innovation drug research and development chain,　　Acquire the accumulation of technology and experience. The global financial turmoil, Zhongxiaolin believes that the medical CRO will have a greater market. In the global pharmaceutical industry, drug research and development outsourcing market has become a lot of enterprisesIndustry's contention. The current global CRO market value of about 20 billion U.S. dollars, and the annual growth rate of 16%, is expected to reach the size of $36 billion by 2010. "Pharmaceutical companies in developed countries are slashing research and development spending and outsourcing more and more research and development to research and development outsourcing companies in India and China under the enormous cost of new drug research and development activities," he said. "" The biopharmaceutical industry should jump out of the past in the medical application of a single path, the future biopharmaceutical industry can be expanded into biomedicine, bio-chemical, bio-energy, bio-agriculture, bio-forestry and other aspects. In this way, biopharmaceutical will have a very wide space. "Last year, the company of the United States and the Blue Mountain, China capital of bio-pesticide enterprises in Jiangxi Province investment 30 million U.S. dollars, the goal is biological agriculture." It is understood that Jiangxi Natural Ecological Industry Co., Ltd. is a leading bio-pesticide enterprises, is also currently China's largest manufacturer of Beauveria Bassiana Pesticide, its independent innovation production of a series of fungal pesticides, to achieve "kill harmful insects, protect the natural enemies of pests, protect the ecological environment, enhance plant immunity" purpose, with high efficiency,　　Pollution-free, no residue, no resistance, green environmental protection and other advantages, can be widely used in biological control of a variety of agricultural and forestry pests. Investors flock to the bio-medicine sector in fact, in recent years, the bio-medicine has already begun to warm up. How popular is this industry? It can be seen from the IPO of a new stock. August 2007, in order to undertake research and development outsourcing concept of the well-known bio-pharmaceutical company Wuxi Pharmaceutical Wuxi listed in the NYSE IPO, access to Europe and the United States, Asia, a large number of wind to subscribe.　　Compared with the IPO price, the shares rose 40%, sold 10.36 million shares, a total of about 185 million U.S. dollars, to become the best performance in the United States one of the top 10 IPOs.　　Last March, SoftBank Asia investment and Shenzhen Innovation Investment jointly invested in China peptide pharmaceutical leader Shenzhen John Woo pharmaceutical Industry, the first 15 million U.S. dollars, but also to become the soft silver in China bio-pharmaceutical business. Why is biomedical medicine so favored? SoftBank's chief partner, Yan, told this reporter that the reason is the general trend: the world's many pharmaceutical giants have invested heavily in the development of such drugs, in the Chinese market has just started, anticipating the future of high-speed growth.　　In the field of chemical medicine in China, the advantages of new drugs are certainly not strong in Europe and America, "the chemical drug competition is too intense," Yan said, "but biopharmaceutical is in the ascendant." Newspaper reporter Wu Jingyan Li Yifi layout linkage See C06 version